| Target Price | $15.81 |
| Price | $0.60 |
| Potential |
2,535.00%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target NeuroBo Pharmaceuticals Inc 2026 .
The average NeuroBo Pharmaceuticals Inc target price is $15.81.
This is
2,535.00%
register free of charge
$22.05
3,575.00%
register free of charge
$5.05
741.67%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend NeuroBo Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the NeuroBo Pharmaceuticals Inc stock has an average upside potential 2026 of
2,535.00%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.56 | -1.07 |
| 44.72% | 69.94% | |
| P/E | negative |
6 Analysts have issued a NeuroBo Pharmaceuticals Inc forecast for earnings per share. The average NeuroBo Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
NeuroBo Pharmaceuticals Inc...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Maxim Group |
Locked
➜
Locked
|
Locked | May 19 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 16 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 21 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 30 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Maxim Group:
Locked
➜
Locked
|
May 19 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 16 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 21 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 30 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


